Blumchen, Katharina
Kleinheinz, Andreas
Klimek, Ludger
Beyer, Kirsten
Anagnostou, Aikaterini
Vogelberg, Christian
Butovas, Sergejus
Ryan, Robert
Norval, David
Zeitler, Stefan
Du Toit, George
Clinical trials referenced in this document:
Documents that mention this clinical trial
▼Palforzia for oral desensitisation to peanut in allergic children
https://doi.org/10.1136/dtb.2022.000044
Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials
https://doi.org/10.1186/s13223-023-00757-8
Documents that mention this clinical trial
Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials
https://doi.org/10.1186/s13223-023-00757-8
Documents that mention this clinical trial
▼Palforzia for oral desensitisation to peanut in allergic children
https://doi.org/10.1136/dtb.2022.000044
Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials
https://doi.org/10.1186/s13223-023-00757-8
Funding for this research was provided by:
Aimmune Therapeutics, a Nestlé Health Science company
Article History
Received: 7 October 2022
Accepted: 2 January 2023
First Online: 13 March 2023
Declarations
:
: All individual trials received approval from institutional review boards or independent ethics committees and were conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the Declaration of Helsinki.
: Written informed consent or assent (as appropriate) was obtained from each participant and/or their caregiver before trial entry.
: KBl reports personal fees and/or grants and/or nonfinancial support from Aimmune Therapeutics, a Nestlé Health Science company, DBV Technologies, HiPP GmbH, Novartis, Allergy Therapeutics, HAL Allergy, ALK, Allergopharma, Nestlé, and Bausch + Lomb, outside the submitted work and other financial and nonfinancial interests from the German Society for Pediatric Allergology & Environmental Medicine (GPA), German Society for Allergology & Clinical Immunology (DGKJ), the German Society for Pediatric Pneumology (GPP), and the German Society of Pneumology (DGP). AK reports study funding, medical writing, honoraria, expert testimony, support for attending meetings/travel, and participation on a data safety monitoring board or advisory board from Aimmune Therapeutics, a Nestlé Health Science company. Other disclosures include AbbVie, Aimmune Therapeutics, a Nestlé Health Science company, Almirall, Galderma, Janssen/JNJ, Leo Pharma, Lilly, Medac, Novartis, and Regeneron/Sanofi. LK reports study funding and medical writing from Aimmune Therapeutics, a Nestlé Health Science company; grants and/or personal fees from Allergopharma, Viatris, HAL Allergy, ALK-Abello, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeutics, AstraZeneca, GSK, ImmunoTek, Cassella-med, Novartis, Regeneron Pharmaceuticals, and ROXALL Medizin GmbH; consulting fees from Allergopharma, Viatris, LETI Pharma, Stallergenes, Sanofi, AstraZeneca, and GSK; payment for expert testimony from GSK and Sanofi; other financial or nonfinancial interests from AeDA, DGHNO, Deutsche Akademi fur Allergologie und klinische immunologie, HNO-BV, GPA, and EAACI. KBe reports study funding, medical writing, and processing charges (payment to institution) from Aimmune Therapeutics, a Nestlé Health Science company; grants or contracts to institution from ALK and DBV Technologies; consulting fees from reports from Aimmune Therapeutics, a Nestlé Health Science company, Bencard, DBV Technologies, and Novartis; payment or honoraria from Aimmune Therapeutics, a Nestlé Health Science company, and Allergopharma; participation on a Data Safety Monitoring Board or Advisory Board from Aimmune Therapeutics, a Nestlé Health Science company, Bencard, DBV Technologies, and Novartis; leadership or fiduciary role in other board, society, committee unpaid from AGATE-Anaphylaxis Training and Education, German Society for Pediatric Allergology & Environmental Medicin, German Society for Allergology & Clinical Immunology (DGKJ), and German Allergy and Asthma Association. AA reports grants from Aimmune Therapeutics, a Nestlé Health Science company, during the conduct of the study; personal fees from DBV Technologies; grants and personal fees from FARE; and personal fees from ALK, outside the submitted work. CV reports study funding and medical writing from Aimmune Therapeutics, a Nestlé Health Science company; honoraria for presentation at the German Allergy Congress from DBV Technologies and honoraria for presentation at the Congress of the German Pediatric Society, press conference and launch symposium. SB reports study funding and medical writing from Aimmune Therapeutics, a Nestlé Health Science company. RR is an employee of Aimmune Therapeutics, a Nestlé Health Science company. DN is an employee of Aimmune Therapeutics, a Nestlé Health Science company. SZ is an employee of Aimmune Therapeutics, a Nestlé Health Science company. GDT reports study funding and medical writing from Aimmune Therapeutics, a Nestlé Health Science company; funding to institution received for active research on Aimmune projects, ARC008, ARC004, and ARC005; active member of Aimmune Therapeutics, a Nestlé Health Science company, scientific board.